Evaluation of clinical and immunological criteria of the effectiveness of intravitreal injection of ranibizumab at macular edema due to retinal vein occlusion

Branch retinal vein occlusion (BRVO) leads to retinal ischemia, releases vascular endothelial growth factor (VEGF) and other cytokines that damage to the blood retinal barrier which causes to macular edema. The aim of the study was to determine the serum and the lacrimal fluid (LF) levels of VEGF-A and IL-6 in their association with clinical parameters in patients with BRVO on the background of ranibizumab treatment. Materials and methods: 32 patients (median age 58.9 years, women - 21) underwent a three month intravitreal ranibizumab injection (IRI) due to macular edema causes BRVO. Ophthalmological examination and spectral domain optical coherence tomography was performed every month. Serum and the LF levels of VEGF-A and IL-6 were measure by ELISA before and after 3 months of treatment with IRI. The control group consist of healthy volunteers in the same age. Results: The visual acuity was improved on the background of the three IRI to 0.3 (±0.1) by Snellen in nonischemic type and 0.15 (±0.04) in ischemic type BRVO. Reduction of the retinal thickness in the macula was obtained in both groups. The serum (714.6±311 pg/ml) and LF level (762.6±432 pg/ml) of VEGF-A were in 2 times higher than in a con-trol and significantly correlated (p=0.0001) with retinal thickness. The serum level of IL-6 was higher than in control in ischemic type BRVO. Ranibizumab treatment resulted to decrease serum and LF level of VEGF-A in all patients in correlation with clinical parameters. LF level of IL-6 was decreased in while non-ischemic type of occlusion. Conclusions: There were determined high serum and lacrimal fluid levels of VEGF-A correlated with retinal thickness in patients with macular edema due to BRVO. Intravitreal ranibizumab injections led to reduced VEGF-A in serum and tear, correlating with improvement in clinical parameters.

окклюзия вен сетчатки, макулярный отек, ишемия сетчатки, антивазопролиферативный фактор роста, ранибизумаб, branch retinal vein occlusion, macular edema, retina ischemia, vascular endothelial growth factor, ranibizumab

1. Злобин И. В., Зайцева Н. В., Юрьева Т. Н., Щуко А. Г. Изменение цитокинового статуса у пациентов с окклюзией вен сетчатки на фоне анти-VEGF терапии // Современные технологии в офтальмологии. 2014. № 1. С. 49-50.

2. Нероев В. В., Слепова О. С., Рябина М. В., Карапетян Л. В. Изменение содержания VEGF в слезной жидкости и сыворотке крови у больных с влажной формой возрастной макулярной дегенерации на фоне лечения препаратом Луцентис // Российский офтальмологический журнал. 2013. № 3. С. 62-65.

3. Тульцева С. Н. Роль воспаления в патогенезе посттромботического макулярного отека. Современные направления медикаментозного лечения // Офтальмологические ведомости. 2012. Т. 5. № 4. С. 35-44.

4. Шеланкова А. В., Михайлова М. А., Андреева И. В. и др. Эффективность антиангиогенной терапии у пациентов с макулярным отеком вследствие окклюзии ветви центральной вены сетчатки // Современные технологии в офтальмологии. 2015. № 3. С. 184-186.

5. Щуко А. Г., Злобин И. В., Юрьева Т. Н. и др. Дисбаланс внутриглазных цитокинов при окклюзии вен сетчатки и его взаимосвязь с эффективностью антиангиогенной терапии // Вестник офтальмологии. 2015. Т. 131. № 2. С. 50-58.

6. Хохлова Д. Ю., Дроздова Е. А. Значение основных маркеров эндотелиальной дисфункции в развитии макулярного отека при окклюзии вен сетчатки // Современные технологии в офтальмологии. 2016. № 4. С. 245-247.

7. Campochiaro P. A., Heier S., Feiner L. et al. BRAVO Investigators Ranibizumab for macular edema following branch retinal vein occlusion: six month primary end point results of phase III study // Ophthalmology. 2010. Vol. 117(6). P. 1102-1112.

8. Campochiaro P. A., Sophie R., Pearlman J. et al. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study // Ophthalmology. 2014. Jan;121(1). P. 209-219.

9. Fujikawa М., Sawada О., Osamu Т. et. al. Correlation between vascular endothelial growth factor and nonperfused areas in macular edema secondary to branch retinal vein occlusion // Clinical Ophthalmology. 2013. Р. 1497-1501.

10. Lee W. J., Kang M. H., Seong M., Cho H. Y. Comparison of aqueous concentrations of angiogenic and inflammatory cytokines in diabetic macular oedema and macular oedema due to branch retinal vein occlusion // Br. J. Ophthalmol. 2012. Vol. 96. P. 1426-1430.

11. Muraoka Y., Tsujikawa А., Murakami Т. et al. Morphologic and functional changes in retinal vessels associated with branch retinal vein occlusion // Ophthalmology. 2013. Vol. 120. № 1. Р. 91-99.

12. McAllister I. L., Tan M. H., Smithies L. A. et al. The effect ofcentral retinal venous pressure in patients with central retinal vein occlusion and a high mean area of nonperfusion // Ophthalmology. 2014. Vol. 121(11). P. 2228-2236.

13. Noma H., Funatsu H., Yamasaki M. Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular edema in branch retinal vein occlusion // Eye. 2008. Vol. 22(1). Р. 42-48.

14. Noma H., Finatsu H., Yamasaki M. et al. Role of soluble endothelial growth factor receptor signalling and other factors or cytokines in central retinal vein occlusion with macular edema // Invest. Ophthalmol. 2015. Vol. 56(2). P. 1122-1128.

15. Rogers S., McIntosh R. L., Cheung N. et al. The prevalence of retinal vein occlusion: Pooled data from population studies from the United States, Europe, Asia, and Australia // Ophthalmology. 2010. Vol. 117. P. 313-319.

16. Scholl S., Augustin A., Loewenstein A. General pathophysiology of macular edema // Eur. J. Ophthalmol. - 2011. Vol. 21(6). Р. 10-19.